CIK 0001178670 · Large accelerated filer
ALNYLAM PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ALNY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 770602661
- Phone
- (617) 551-8200
- Business address
- 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE, MA, 02142
- Former names
- ALNYLAM PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $543,126
- in 2 filings
- Open-market sales, last 90 days
- $398,855
- in 1 filing
Net +$144,271. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-03 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −29 | $246.18 | $7K | 28,014 |
| 2025-03-03 | Tanguler Tolga EVP, Chief Commercial Officer | Sale | −3 | $247.35 | $742 | 28,011 |
| 2025-03-03 | Tanguler Tolga EVP, Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +7,819 | 7,819 | ||
| 2025-03-03 | Garg Pushkal CMO & EVP Dev & Med Affairs | Grant or award 10b5-1 | +14,137 | 27,099 | ||
| 2025-03-03 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −213 | $242.37 | $52K | 26,886 |
| 2025-03-03 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −235 | $243.36 | $57K | 26,651 |
| 2025-03-03 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −158 | $244.41 | $39K | 26,493 |
| 2025-03-03 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −116 | $245.26 | $28K | 26,377 |
| 2025-03-03 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −48 | $246.18 | $12K | 26,329 |
| 2025-03-03 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −5 | $247.35 | $1K | 26,324 |
| 2025-03-03 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −1 | $248.36 | $248 | 26,323 |
| 2025-03-03 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −583 | $243.13 | $142K | 25,740 |
| 2025-03-03 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −273 | $244.43 | $67K | 25,467 |
| 2025-03-03 | Garg Pushkal CMO & EVP Dev & Med Affairs | Sale 10b5-1 | −117 | $245.53 | $29K | 25,350 |
| 2025-03-03 | Garg Pushkal CMO & EVP Dev & Med Affairs | Grant or award · Stock Option (right to buy) 10b5-1 | +7,819 | 7,819 | ||
| 2025-03-03 | Poulton Jeffrey V. EVP, Chief Financial Officer | Grant or award | +15,117 | 49,015 | ||
| 2025-03-03 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −350 | $242.37 | $85K | 48,665 |
| 2025-03-03 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −382 | $243.36 | $93K | 48,283 |
| 2025-03-03 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −258 | $244.41 | $63K | 48,025 |
| 2025-03-03 | Poulton Jeffrey V. EVP, Chief Financial Officer | Sale | −189 | $245.26 | $46K | 47,836 |
Page 32 of 41 · 816 trades